Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting

Nine abstracts accepted, including two oral presentations

HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported that eight abstracts–including two oral presentations–on the Company’s lead product candidate rivo-cel (formerly BPX-501), in addition to an abstract on its controllable CAR program, were accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting.

Among the highlights will be late interim analyses from the BP-004 trial in children with acute leukemias and nonmalignant blood diseases, as well as the comparator C-004 trial—a multicenter, observational study of similar pediatric patients receiving a matched unrelated donor (MUD) transplant. As part of these interim analyses, the presentations will include the first reports of transplant Event-Free Survival at 180 days, the primary endpoint of the studies that will serve as the basis for MAA filing in Europe. In addition, longer term follow-up of disease outcomes from several patient subsets, including ALL, AML, thalassemia major, and Fanconi anemia, will be presented. Finally, the cumulative clinical experience of patients in BP-004 who received rimiducid to treat steroid refractory Graft-versus-Host-Disease will also be presented. ASH 2018 is being held in San Diego, California on December 1-4.

RIVO-CEL PRESENTATION DETAILS

Poster Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders”
Abstract Number: 2171
Session Name: 732. Clinical Allogeneic Transplantation: Results: Poster I
Session Date:Saturday, December 1, 2018
Presentation Time:6:15 p.m.8:15 p.m. PT

Oral Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias”
Abstract Number: 307
Session Name: 732. Clinical Allogeneic Transplantation: Results: Optimizing Outcomes After Allogeneic Transplantation 
Session Date:Sunday, December 2, 2018
Session Time:7:30 a.m. - 9:00 a.m. PT
Presentation Time:7:30 a.m. PT

Oral Presentation: “Administration of BPX-501 Following αβ T and B-cell Depleted Haplo-HSCT in Children with Transfusion-Dependent Thalassemia”
Abstract Number: 166
Session Name: 112. Thalassemia and Globin Gene Regulation: Clinical
Session Date:Saturday, December 1, 2018
Session Time:2:00 p.m. - 3:30 p.m. PT
Presentation Time:2:45 p.m. PT

Poster Presentation: “Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-versus-Host-Disease  (GvHD)”
Abstract Number: 2207
Session Name: 801. Gene Therapy and Transfer: Poster I
Session Date:Saturday, December 1, 2018
Presentation Time:6:15 p.m. - 8:15 p.m. PT

Poster Presentation: “Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies”
Abstract Number: 4534
Session Name: 703. Adoptive Immunotherapy: Poster III 
Session Date:Monday, December 3, 2018 
Presentation Time:6:00 p.m. - 8:00 p.m. PT

Poster Presentation: “Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion”
Abstract Number: 3496 
Session Name: 801. Gene Therapy and Transfer: Poster II 
Session Date:Sunday, December 2, 2018
Presentation Time:6:00 p.m. - 8:00 p.m. PT

Poster Presentation: “Administration of BPX-501 Cells Following αβ T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia”
Abstract Number: 4654
Session Name: 732. Clinical Allogeneic Transplantation: Results: Poster III
Session Date:Monday, December 3, 2018
Presentation Time:6:00 p.m. - 8:00 p.m. PT

Poster Presentation: “A Simplified Method for Transduction and Expansion of T Cells for Clinical Application”
Abstract Number: 4555 
Session Name: 711. Cell Collection and Processing: Poster III 
Session Date:Monday, December 3, 2018 
Presentation Time:6:00 p.m. - 8:00 p.m. PT

CONTROLLABLE CAR PRESENTATION DETAILS

Poster Presentation: “Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40”
Abstract Number: 4550
Session Name: 703. Adoptive Immunotherapy: Poster III   
Session Date:Monday, December 3, 2018 
Presentation Time: 6:00 p.m. - 8:00 p.m. PT 

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-cel, is an allogeneic polyclonal T cell product that has shown promising results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@soleburytrout.com

Bellicum Logo.jpg

Source: Bellicum Pharmaceuticals, Inc.